StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a research note released on Friday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Trading Down 1.9 %
Shares of NASDAQ:EVOK opened at $5.09 on Friday. Evoke Pharma has a 12-month low of $3.54 and a 12-month high of $17.88. The business’s fifty day simple moving average is $4.82 and its 200-day simple moving average is $5.62. The company has a market capitalization of $43.76 million, a PE ratio of -2.78 and a beta of 0.39.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). Evoke Pharma had a negative net margin of 86.74% and a negative return on equity of 964.25%. The company had revenue of $2.55 million during the quarter.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Read More
- Five stocks we like better than Evoke Pharma
- Want to Profit on the Downtrend? Downtrends, Explained.
- Whirlpool’s High Dividend Yield Is Too Good to Pass Up
- Health Care Stocks Explained: Why You Might Want to Invest
- Holiday Spending Boom Ahead: 3 BNPL Stocks Poised for Gains
- Energy and Oil Stocks Explained
- Boeing: A Perfect Storm of Trouble Is a Loaded Buying Opportunity
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
